N-Methyl-3,4-methylenedioxyamphetamine
"N-Methyl-3,4-methylenedioxyamphetamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
| Descriptor ID |
D018817
|
| MeSH Number(s) |
D02.092.471.683.152.670
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "N-Methyl-3,4-methylenedioxyamphetamine".
Below are MeSH descriptors whose meaning is more specific than "N-Methyl-3,4-methylenedioxyamphetamine".
This graph shows the total number of publications written about "N-Methyl-3,4-methylenedioxyamphetamine" by people in this website by year, and whether "N-Methyl-3,4-methylenedioxyamphetamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 1 | 3 |
| 2007 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "N-Methyl-3,4-methylenedioxyamphetamine" by people in Profiles.
-
MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. J Psychiatr Res. 2022 05; 149:128-135.
-
The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD. Med Hypotheses. 2021 Jan; 146:110367.
-
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018 06; 5(6):486-497.
-
Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol. 2017 08; 31(8):967-974.
-
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 2016 May; 3(5):481-8.
-
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol. 2013 Jan; 27(1):28-39.
-
Rats preexposed to MDMA display attenuated responses to its aversive effects in the absence of persistent monoamine depletions. Psychopharmacology (Berl). 2011 Aug; 216(3):441-9.
-
Role of five synthetic reaction conditions on the stable isotopic composition of 3,4-methylenedioxymethamphetamine. Anal Chem. 2010 Jul 01; 82(13):5484-9.
-
Supported liquid-liquid extraction of the active ingredient (3,4-methylenedioxymethylamphetamine) from ecstasy tablets for isotopic analysis. J Chromatogr A. 2008 Jan 18; 1178(1-2):1-8.
-
Assessment of club drug use in a treatment-seeking sample of individuals with marijuana dependence. Am J Addict. 2007 Nov-Dec; 16(6):484-7.